LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article: Effect of Nano-Magnesium Oxide on the Expansion Performance and Hydration Process of Cement-Based Materials.

    Ye, Yuxun / Liu, Yanming / Shi, Tao / Hu, Zhuojun / Zhong, Lei / Wang, Haobo / Chen, Yaohui

    Materials (Basel, Switzerland)

    2021  Volume 14, Issue 13

    Abstract: Many scholars are concerned about the effect of nano-MgO as an expansion agent on the performance of cement-based materials at an early age, but over a long period less attention is paid to expansion stability and mechanical properties. This article ... ...

    Abstract Many scholars are concerned about the effect of nano-MgO as an expansion agent on the performance of cement-based materials at an early age, but over a long period less attention is paid to expansion stability and mechanical properties. This article examines the influence of nano-MgO on the long-term consistency, fluidity, expansion stability, hydration, and mechanical properties of 30% fly ash cement-based materials and improves research into nano-MgO as an expansion agent. Expansion performance, flexural and compressive strength, and stability after boiling and autoclave treatment were tested for specimens mixed with a 2, 4, 6, 8 and 10% cementitious material mass of nano-MgO. X-ray diffraction (XRD) and scanning electronic microscopy (SEM) were employed to study their hydration process and microstructure. The results showed that nano-MgO had an obvious effect on the consistency, fluidity and expansion performance of cement paste. After curing in water for 365 days and autoclaving thereafter, the hydration of nano-MgO was relatively complete. The volumetric expansion pressure of the magnesium hydroxide (Mg(OH)
    Language English
    Publishing date 2021-07-05
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2487261-1
    ISSN 1996-1944
    ISSN 1996-1944
    DOI 10.3390/ma14133766
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The Value of a Seven-Autoantibody Panel Combined with the Mayo Model in the Differential Diagnosis of Pulmonary Nodules.

    Ling, Zhougui / Chen, Jifei / Wen, Zhongwei / Wei, Xiaomou / Su, Rui / Tang, Zhenming / Hu, Zhuojun

    Disease markers

    2021  Volume 2021, Page(s) 6677823

    Abstract: Background: Identifying malignant pulmonary nodules and detecting early-stage lung cancer (LC) could reduce mortality. This study investigated the clinical value of a seven-autoantibody (7-AAB) panel in combination with the Mayo model for the early ... ...

    Abstract Background: Identifying malignant pulmonary nodules and detecting early-stage lung cancer (LC) could reduce mortality. This study investigated the clinical value of a seven-autoantibody (7-AAB) panel in combination with the Mayo model for the early detection of LC and distinguishing benign from malignant pulmonary nodules (MPNs).
    Methods: The concentrations of the elements of a 7-AAB panel were quantitated by enzyme-linked immunosorbent assay (ELISA) in 806 participants. The probability of MPNs was calculated using the Mayo predictive model. The performances of the 7-AAB panel and the Mayo model were analyzed by receiver operating characteristic (ROC) analyses, and the difference between groups was evaluated by chi-square tests (
    Results: The combined area under the ROC curve (AUC) for all 7 AABs was higher than that of a single one. The sensitivities of the 7-AAB panel were 67.5% in the stage I-II LC patients and 60.3% in the stage III-IV patients, with a specificity of 89.6% for the healthy controls and 83.1% for benign lung disease patients. The detection rate of the 7-AAB panel in the early-stage LC patients was higher than that of traditional tumor markers. The AUC of the 7-AAB panel in combination with the Mayo model was higher than that of the 7-AAB panel alone or the Mayo model alone in distinguishing MPN from benign nodules. For early-stage MPN, the sensitivity and specificity of the combination were 93.5% and 58.0%, respectively. For advanced-stage MPN, the sensitivity and specificity of the combination were 91.4% and 72.8%, respectively. The combination of the 7-AAB panel with the Mayo model significantly improved the detection rate of MPN, but the positive predictive value (PPV) and the specificity were not improved when compared with either the 7-AAB panel alone or the Mayo model alone.
    Conclusion: Our study confirmed the clinical value of the 7-AAB panel for the early detection of lung cancer and in combination with the Mayo model could be used to distinguish benign from malignant pulmonary nodules.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Autoantibodies/immunology ; Biomarkers, Tumor/immunology ; Biomarkers, Tumor/standards ; Diagnosis, Differential ; Female ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/immunology ; Male ; Middle Aged ; Predictive Value of Tests ; Solitary Pulmonary Nodule/diagnosis ; Solitary Pulmonary Nodule/immunology
    Chemical Substances Autoantibodies ; Biomarkers, Tumor
    Language English
    Publishing date 2021-02-18
    Publishing country United States
    Document type Clinical Trial ; Journal Article
    ZDB-ID 604951-5
    ISSN 1875-8630 ; 0278-0240
    ISSN (online) 1875-8630
    ISSN 0278-0240
    DOI 10.1155/2021/6677823
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: LncRNA TGFB2-AS1 regulates lung adenocarcinoma progression via act as a sponge for miR-340-5p to target EDNRB expression.

    Ling, Zhougui / Wen, Zhongwei / Tang, Zhenming / Chen, Jifei / Mo, Shanyin / Wei, Xiaomou / Hu, Zhuojun

    American journal of translational research

    2020  Volume 12, Issue 7, Page(s) 3813–3821

    Abstract: Long non-coding RNA TGFB2-antisense RNA1 (TGFB2-AS1) has been reported could regulate tumorigenesis. However, the roles of TGFB2-AS1 in lung adenocarcinoma (LUAD) remain largely unknown. In this work, we aimed to explore the expression levels of TGFB2- ... ...

    Abstract Long non-coding RNA TGFB2-antisense RNA1 (TGFB2-AS1) has been reported could regulate tumorigenesis. However, the roles of TGFB2-AS1 in lung adenocarcinoma (LUAD) remain largely unknown. In this work, we aimed to explore the expression levels of TGFB2-AS1 and mechanisms in regulating LUAD progression. Expression level of TGFB2-AS1 in LUAD tissues and normal tissues was analyzed at StarBase. Moreover, its expression in LUAD cells and normal cell was analyzed with quantitative real-time polymerase chain reaction method. Gain- and loss-of-function studies were conducted to analyze the biological roles of TGFB2-AS1 in LUAD. Results indicated TGFB2-AS1 was evidently downregulated in LUAD tissues and cells. Moreover, as analyzed by cell counting kit-8 assay, wound-healing and transwell invasion assays, results revealed TGFB2-AS1 overexpression could suppress proliferation, migration and invasion abilities of LUAD cells in vitro and tumor growth in vivo. In addition, LncBase V2.0 and TargetScan prediction tools showed TGFB2-AS1 and endothelin receptor type B (EDNRB) shares binding site in microRNA-340-5p (miR-340-5p). Furthermore, luciferase activity reporter assay and RT-qPCR assay validated these prediction results. Furthermore, we showed TGFB2-AS1 functions as sponge for miR-340-5p to regulate EDNRB expression. Collectively, our results indicated TGFB2-AS1/miR-340-5p/EDNRB axis plays crucial roles in regulating LUAD progression, indicating TGFB2-AS1 may be a novel therapeutic target for LUAD.
    Language English
    Publishing date 2020-07-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2471058-1
    ISSN 1943-8141
    ISSN 1943-8141
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Carbon monoxide poisoning: a prediction model using meteorological factors and air pollutant.

    Ruan, Hai-Lin / Deng, Wang-Shen / Wang, Yao / Chen, Jian-Bing / Hong, Wei-Liang / Ye, Shan-Shan / Hu, Zhuo-Jun

    BMC proceedings

    2021  Volume 15, Issue Suppl 1, Page(s) 1

    Abstract: Background: While the influence of meteorology on carbon monoxide (CO) poisoning has been reported, few data are available on the association between air pollutants and the prediction of CO poisoning. Our objective is to explore meteorological and ... ...

    Abstract Background: While the influence of meteorology on carbon monoxide (CO) poisoning has been reported, few data are available on the association between air pollutants and the prediction of CO poisoning. Our objective is to explore meteorological and pollutant patterns associated with CO poisoning and to establish a predictive model.
    Results: CO poisoning was found to be significantly associated with meteorological and pollutant patterns: low temperatures, low wind speeds, low air concentrations of sulfur dioxide (SO
    Conclusion: Low temperatures, wind speed, and SO
    Language English
    Publishing date 2021-03-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 2411867-9
    ISSN 1753-6561
    ISSN 1753-6561
    DOI 10.1186/s12919-021-00206-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.

    Wen, Zhineng / Huang, Ying / Ling, Zhougui / Chen, Jifei / Wei, Xiaomou / Su, Rui / Tang, Zhenming / Wen, Zhongwei / Deng, Youping / Hu, Zhuojun

    Disease markers

    2020  Volume 2020, Page(s) 4716793

    Abstract: Background: Lung cancer (LC) is top-ranked in cancer incidence and is the leading cause of cancer death globally. Combining serum biomarkers can improve the accuracy of LC diagnosis. The identification of the best potential combination of traditional ... ...

    Abstract Background: Lung cancer (LC) is top-ranked in cancer incidence and is the leading cause of cancer death globally. Combining serum biomarkers can improve the accuracy of LC diagnosis. The identification of the best potential combination of traditional tumor markers is essential for LC diagnosis.
    Results: As single markers, CYFR21 and CEA showed good diagnostic efficacy for nonsmall cell lung cancer (NSCLC) patients, while NSE and CEA were the most sensitive in the diagnosis of small cell lung cancer (SCLC). The area under the curve (AUC) value was 0.854 for the panel of four biomarkers (CYFR21, CEA, NSE, and SCC), 0.875 for the panel of six biomarkers (CYFR21, CEA, NSE, SCC, CA125, and CA15-3), and 0.884 for the panel of ten markers (CYFR21, CEA, NSE, SCC, CA125, CA15-3, CA19-9, CA50, CA242, and CA724). With a higher sensitivity and negative predictive value (NPV), the diagnostic accuracy of the three panels was better than that of any single biomarker, but there were no statistically significant differences among them (all
    Conclusion: The biomarkers isolated are elevated for different types of lung cancer, and the panel of CYFR21, CEA, NSE, and SCC seems to be a promising serum biomarker for the diagnosis of lung cancer, while the combination with carbohydrate antigen markers does not improve the diagnostic efficacy.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antigens, Tumor-Associated, Carbohydrate/blood ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/standards ; Female ; Humans ; Lung Neoplasms/blood ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Predictive Value of Tests
    Chemical Substances Antigens, Tumor-Associated, Carbohydrate ; Biomarkers, Tumor
    Language English
    Publishing date 2020-12-10
    Publishing country United States
    Document type Evaluation Study ; Journal Article
    ZDB-ID 604951-5
    ISSN 1875-8630 ; 0278-0240
    ISSN (online) 1875-8630
    ISSN 0278-0240
    DOI 10.1155/2020/4716793
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: [Value of detecting p16 gene methylation in the diagnosis of malignant pleural effusion].

    Liu, Da-ying / Zhou, Feng-li / Hu, Zhuo-jun / Hu, Hong-bo

    Nan fang yi ke da xue xue bao = Journal of Southern Medical University

    2010  Volume 30, Issue 9, Page(s) 2148–2150

    Abstract: Objective: To investigate aberrant methylation in the promoter of p16 gene in the sediment cells of pleural effusion and evaluate its clinical significance in the differentiating benign and malignant pleural effusion.: Methods: Using methylation- ... ...

    Abstract Objective: To investigate aberrant methylation in the promoter of p16 gene in the sediment cells of pleural effusion and evaluate its clinical significance in the differentiating benign and malignant pleural effusion.
    Methods: Using methylation-specific PCR (MSP), aberrant promoter methylation of p16 gene was detected in the sedimental cells of pleural effusion samples from 66 patients with pleural effusion.
    Results: Of the 66 patients with pleural effusion, 36 had a definite diagnosis of malignant pleural effusion, and the rest were confirmed to have benign pleural effusion. The positivity rate of p16 gene promoter methylation was 69.4% (25/36) in malignant pleural effusion and 13.3% (4/30) in benign pleural effusion specimens, showing a significant difference between them (χ² = 20.915, P < 0.01). The diagnostic sensitivity, specificity and accuracy of aberrant promoter methylation of p16 gene in the 36 malignant cases were 69.4%, 86.7% and 77.3%, respectively. The positive expression of p16 gene promoter methylation in malignant pleural effusion was not correlated to the histological type or the pathological grade of the tumor (P > 0.05).
    Conclusion: Detection of aberrant methylation in p16 gene promoter in the sediment cells of pleural effusion specimens by MSP method allows differentiation between benign and malignant pleural effusion.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Base Sequence ; DNA Methylation ; Female ; Genes, p16 ; Humans ; Male ; Middle Aged ; Molecular Sequence Data ; Pleural Effusion, Malignant/diagnosis ; Pleural Effusion, Malignant/genetics ; Promoter Regions, Genetic/genetics ; Sensitivity and Specificity
    Language Chinese
    Publishing date 2010-09
    Publishing country China
    Document type English Abstract ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2250951-3
    ISSN 1673-4254
    ISSN 1673-4254
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: [Clinical value of monitoring serum cardiac biomarkers in pulmonary thromboembolism-induced myocardial injury].

    Hu, Zhuo-jun / Zhou, Yu-Qi / Zhang, Hai-bo / Li, Li

    Nan fang yi ke da xue xue bao = Journal of Southern Medical University

    2008  Volume 28, Issue 10, Page(s) 1853–1855

    Abstract: Objective: To investigate the clinical value of monitoring the serum cardiac biomarkers in patients with pulmonary thromboembolism (PTE) and secondary myocardial injury.: Methods: The serum cardiac biomarkers including aspartate aminotransferase (AST) ...

    Abstract Objective: To investigate the clinical value of monitoring the serum cardiac biomarkers in patients with pulmonary thromboembolism (PTE) and secondary myocardial injury.
    Methods: The serum cardiac biomarkers including aspartate aminotransferase (AST), lactate dehydrogenase (LDH), alpha-hydroxybutyrate dehydrogenase (HBDH), creatine kinase (CK), creatine kinase isoenzyme (CK-MB), cardiac tropnin I (cTnI) and myoglobin (Myo) were measured using immunochemiluminescent assays in 36 patients with PTE, who were diagnosed according to imaging findings in the recent 5 years. The measurements in concomitant non-PTE patients free of heart, liver, or kidney diseases were used as the baseline values of the biomarkers. Correlation analysis of the measurements was conducted in relation to the pulmonary embolism area, pulmonary hypertension and mortality rate.
    Results: The PTE patients exhibited significantly elevated levels of the serum cardiac biomarkers including AST (56.14-/+15.73 U/L), LDH (303.06-/+94.99 U/L), HBDH (234.67-/+87.86 U/L), CK-MB (26.19-/+12.39 U/L), CK (129.25-/+76.14 U/L), Myo (70.63-/+45.75 ng/ml), and cTnI (0.45-/+0.41 ng/ml) in comparison with the baseline values (P < 0.01). Of these biomarkers, AST and CK-MB showed a significant correlation to the mortality, cTnI was correlated to pulmonary hypertension, and Myo was correlated to pulmonary hypertension and massive pulmonary embolism.
    Conclusion: Measurements of these serum cardiac biomarkers may serve as indicators for diagnosis of myocardial injury secondary to PTE. AST, CK-MB, cTnI, and Myo can help assess the prognosis of the patients.
    MeSH term(s) Adult ; Aged ; Aspartate Aminotransferases/blood ; Biomarkers/blood ; Creatine Kinase, MB Form/blood ; Female ; Humans ; L-Lactate Dehydrogenase/blood ; Male ; Middle Aged ; Myocardial Ischemia/blood ; Myocardial Ischemia/etiology ; Pulmonary Embolism/blood ; Pulmonary Embolism/complications
    Chemical Substances Biomarkers ; L-Lactate Dehydrogenase (EC 1.1.1.27) ; Aspartate Aminotransferases (EC 2.6.1.1) ; Creatine Kinase, MB Form (EC 2.7.3.2)
    Language Chinese
    Publishing date 2008-10
    Publishing country China
    Document type English Abstract ; Journal Article
    ZDB-ID 2250951-3
    ISSN 1673-4254
    ISSN 1673-4254
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Book ; Online: TAO Conceptual Design Report

    JUNO Collaboration / Abusleme, Angel / Adam, Thomas / Ahmad, Shakeel / Aiello, Sebastiano / Akram, Muhammad / Ali, Nawab / An, Fengpeng / An, Guangpeng / An, Qi / Andronico, Giuseppe / Anfimov, Nikolay / Antonelli, Vito / Antoshkina, Tatiana / Asavapibhop, Burin / de André, João Pedro Athayde Marcondes / Auguste, Didier / Babic, Andrej / Baldini, Wander /
    Barresi, Andrea / Baussan, Eric / Bellato, Marco / Bergnoli, Antonio / Bernieri, Enrico / Biare, David / Birkenfeld, Thilo / Blin, Sylvie / Blum, David / Blyth, Simon / Bolshakova, Anastasia / Bongrand, Mathieu / Bordereau, Clément / Breton, Dominique / Brigatti, Augusto / Brugnera, Riccardo / Budano, Antonio / Buscemi, Mario / Busto, Jose / Butorov, Ilya / Cabrera, Anatael / Cai, Hao / Cai, Xiao / Cai, Yanke / Cai, Zhiyan / Cammi, Antonio / Campeny, Agustin / Cao, Chuanya / Cao, Guofu / Cao, Jun / Caruso, Rossella / Cerna, Cédric / Chakaberia, Irakli / Chang, Jinfan / Chang, Yun / Chen, Pingping / Chen, Po-An / Chen, Shaomin / Chen, Shenjian / Chen, Xurong / Chen, Yi-Wen / Chen, Yixue / Chen, Yu / Chen, Zhang / Cheng, Jie / Cheng, Yaping / Chepurnov, Alexander / Chiesa, Davide / Chimenti, Pietro / Chukanov, Artem / Chuvashova, Anna / Claverie, Gérard / Clementi, Catia / Clerbaux, Barbara / Di Lorenzo, Selma Conforti / Corti, Daniele / Costa, Salvatore / Corso, Flavio Dal / De La Taille, Christophe / Deng, Jiawei / Deng, Zhi / Deng, Ziyan / Depnering, Wilfried / Diaz, Marco / Ding, Xuefeng / Ding, Yayun / Dirgantara, Bayu / Dmitrievsky, Sergey / Dohnal, Tadeas / Donchenko, Georgy / Dong, Jianmeng / Dornic, Damien / Doroshkevich, Evgeny / Dracos, Marcos / Druillole, Frédéric / Du, Shuxian / Dusini, Stefano / Dvorak, Martin / Enqvist, Timo / Enzmann, Heike / Fabbri, Andrea / Fajt, Lukas / Fan, Donghua / Fan, Lei / Fang, Can / Fang, Jian / Fatkina, Anna / Fedoseev, Dmitry / Fekete, Vladko / Feng, Li-Cheng / Feng, Qichun / Ford, Richard / Formozov, Andrey / Fournier, Amélie / Gan, Haonan / Gao, Feng / Garfagnini, Alberto / Göttel, Alexandre / Genster, Christoph / Giammarchi, Marco / Giaz, Agnese / Giudice, Nunzio / Giuliani, Franco / Gonchar, Maxim / Gong, Guanghua / Gong, Hui / Gorchakov, Oleg / Gornushkin, Yuri / Grassi, Marco / Grewing, Christian / Gromov, Maxim / Gromov, Vasily / Gu, Minghao / Gu, Xiaofei / Gu, Yu / Guan, Mengyun / Guardone, Nunzio / Gul, Maria / Guo, Cong / Guo, Jingyuan / Guo, Wanlei / Guo, Xinheng / Guo, Yuhang / Haacke, Michael / Hackspacher, Paul / Hagner, Caren / Han, Ran / Han, Yang / He, Miao / He, Wei / Heinz, Tobias / Hellmuth, Patrick / Heng, Yuekun / Herrera, Rafael / Hong, Daojin / Hou, Shaojing / Hsiung, Yee / Hu, Bei-Zhen / Hu, Hang / Hu, Jianrun / Hu, Jun / Hu, Shouyang / Hu, Tao / Hu, Zhuojun / Huang, Chunhao / Huang, Guihong / Huang, Hanxiong / Huang, Qinhua / Huang, Wenhao / Huang, Xingtao / Huang, Yongbo / Hui, Jiaqi / Huo, Lei / Huo, Wenju / Huss, Cédric / Hussain, Safeer / Insolia, Antonio / Ioannisian, Ara / Isocrate, Roberto / Jen, Kuo-Lun / Ji, Xiaolu / Ji, Xingzhao / Jia, Huihui / Jia, Junji / Jian, Siyu / Jiang, Di / Jiang, Xiaoshan / Jin, Ruyi / Jing, Xiaoping / Jollet, Cécile / Joutsenvaara, Jari / Jungthawan, Sirichok / Kalousis, Leonidas / Kampmann, Philipp / Kang, Li / Karagounis, Michael / Kazarian, Narine / Khan, Amir / Khan, Waseem / Khosonthongkee, Khanchai / Kinz, Patrick / Korablev, Denis / Kouzakov, Konstantin / Krasnoperov, Alexey / Krokhaleva, Svetlana / Krumshteyn, Zinovy / Kruth, Andre / Kutovskiy, Nikolay / Kuusiniemi, Pasi / Lachenmaier, Tobias / Landini, Cecilia / Leblanc, Sébastien / Lefevre, Frederic / Lei, Liping / Lei, Ruiting / Leitner, Rupert / Leung, Jason / Li, Chao / Li, Demin / Li, Fei / Li, Fule / Li, Haitao / Li, Huiling / Li, Jiaqi / Li, Jin / Li, Kaijie / Li, Mengzhao / Li, Nan / Li, Qingjiang / Li, Ruhui / Li, Shanfeng / Li, Shuaijie / Li, Tao / Li, Teng / Li, Weidong / Li, Weiguo / Li, Xiaomei / Li, Xiaonan / Li, Xinglong / Li, Yi / Li, Yufeng / Li, Zhibing / Li, Ziyuan / Liang, Hao / Liang, Jingjing / Liebau, Daniel / Limphirat, Ayut / Limpijumnong, Sukit / Lin, Guey-Lin / Lin, Shengxin / Lin, Tao / Ling, Jiajie / Lippi, Ivano / Liu, Fang / Liu, Haidong / Liu, Hongbang / Liu, Hongjuan / Liu, Hongtao / Liu, Hu / Liu, Hui / Liu, Jianglai / Liu, Jinchang / Liu, Min / Liu, Qian / Liu, Qin / Liu, Runxuan / Liu, Shuangyu / Liu, Shubin / Liu, Shulin / Liu, Xiaowei / Liu, Yan / Lokhov, Alexey / Lombardi, Paolo / Lombardo, Claudio / Loo, Kai / Lu, Chuan / Lu, Haoqi / Lu, Jingbin / Lu, Junguang / Lu, Shuxiang / Lu, Xiaoxu / Lubsandorzhiev, Bayarto / Lubsandorzhiev, Sultim / Ludhova, Livia / Luo, Fengjiao / Luo, Guang / Luo, Pengwei / Luo, Shu / Luo, Wuming / Lyashuk, Vladimir / Ma, Qiumei / Ma, Si / Ma, Xiaoyan / Ma, Xubo / Maalmi, Jihane / Malyshkin, Yury / Mantovani, Fabio / Manzali, Francesco / Mao, Xin / Mao, Yajun / Mari, Stefano M. / Marini, Filippo / Marium, Sadia / Martellini, Cristina / Martin-Chassard, Gisele / Martini, Agnese / Mayilyan, Davit / Müller, Axel / Meng, Yue / Meregaglia, Anselmo / Meroni, Emanuela / Meyhöfer, David / Mezzetto, Mauro / Miller, Jonathan / Miramonti, Lino / Monforte, Salvatore / Montini, Paolo / Montuschi, Michele / Morozov, Nikolay / Muralidharan, Pavithra / Nastasi, Massimiliano / Naumov, Dmitry V. / Naumova, Elena / Nemchenok, Igor / Nikolaev, Alexey / Ning, Feipeng / Ning, Zhe / Nunokawa, Hiroshi / Oberauer, Lothar / Ochoa-Ricoux, Juan Pedro / Olshevskiy, Alexander / Orestano, Domizia / Ortica, Fausto / Pan, Hsiao-Ru / Paoloni, Alessandro / Parkalian, Nina / Parmeggiano, Sergio / Payupol, Teerapat / Pei, Yatian / Pelliccia, Nicomede / Peng, Anguo / Peng, Haiping / Perrot, Frédéric / Petitjean, Pierre-Alexandre / Petrucci, Fabrizio / Rico, Luis Felipe Piñeres / Popov, Artyom / Poussot, Pascal / Pratumwan, Wathan / Previtali, Ezio / Qi, Fazhi / Qi, Ming / Qian, Sen / Qian, Xiaohui / Qiao, Hao / Qin, Zhonghua / Qiu, Shoukang / Rajput, Muhammad / Ranucci, Gioacchino / Raper, Neill / Re, Alessandra / Rebber, Henning / Rebii, Abdel / Ren, Bin / Ren, Jie / Rezinko, Taras / Ricci, Barbara / Robens, Markus / Roche, Mathieu / Rodphai, Narongkiat / Romani, Aldo / Roskovec, Bedřich / Roth, Christian / Ruan, Xiangdong / Ruan, Xichao / Rujirawat, Saroj / Rybnikov, Arseniy / Sadovsky, Andrey / Saggese, Paolo / Salamanna, Giuseppe / Sanfilippo, Simone / Sangka, Anut / Sanguansak, Nuanwan / Sawangwit, Utane / Sawatzki, Julia / Sawy, Fatma / Schever, Michaela / Schuler, Jacky / Schwab, Cédric / Schweizer, Konstantin / Selivanov, Dmitry / Selyunin, Alexandr / Serafini, Andrea / Settanta, Giulio / Settimo, Mariangela / Shahzad, Muhammad / Shi, Gang / Shi, Jingyan / Shi, Yongjiu / Shutov, Vitaly / Sidorenkov, Andrey / Simkovic, Fedor / Sirignano, Chiara / Siripak, Jaruchit / Sisti, Monica / Slupecki, Maciej / Smirnov, Mikhail / Smirnov, Oleg / Sogo-Bezerra, Thiago / Songwadhana, Julanan / Soonthornthum, Boonrucksar / Sotnikov, Albert / Sramek, Ondrej / Sreethawong, Warintorn / Stahl, Achim / Stanco, Luca / Stankevich, Konstantin / Stefanik, Dus / Steiger, Hans / Steinmann, Jochen / Sterr, Tobias / Stock, Matthias Raphael / Strati, Virginia / Studenikin, Alexander / Sun, Gongxing / Sun, Shifeng / Sun, Xilei / Sun, Yongjie / Sun, Yongzhao / Suwonjandee, Narumon / Szelezniak, Michal / Tang, Jian / Tang, Qiang / Tang, Quan / Tang, Xiao / Tietzsch, Alexander / Tkachev, Igor / Tmej, Tomas / Treskov, Konstantin / Triossi, Andrea / Troni, Giancarlo / Trzaska, Wladyslaw / Tuve, Cristina / van Waasen, Stefan / Boom, Johannes Vanden / Vanroyen, Guillaume / Vassilopoulos, Nikolaos / Vedin, Vadim / Verde, Giuseppe / Vialkov, Maxim / Viaud, Benoit / Volpe, Cristina / Vorobel, Vit / Votano, Lucia / Walker, Pablo / Wang, Caishen / Wang, Chung-Hsiang / Wang, En / Wang, Guoli / Wang, Jian / Wang, Jun / Wang, Kunyu / Wang, Lu / Wang, Meifen / Wang, Meng / Wang, Ruiguang / Wang, Siguang / Wang, Wei / Wang, Wenshuai / Wang, Xi / Wang, Xiangyue / Wang, Yangfu / Wang, Yaoguang / Wang, Yi / Wang, Yifang / Wang, Yuanqing / Wang, Yuman / Wang, Zhe / Wang, Zheng / Wang, Zhimin / Wang, Zongyi / Watcharangkool, Apimook / Wei, Lianghong / Wei, Wei / Wei, Yadong / Wen, Liangjian / Wiebusch, Christopher / Wong, Steven Chan-Fai / Wonsak, Bjoern / Wu, Diru / Wu, Fangliang / Wu, Qun / Wu, Wenjie / Wu, Zhi / Wurm, Michael / Wurtz, Jacques / Wysotzki, Christian / Xi, Yufei / Xia, Dongmei / Xie, Yuguang / Xie, Zhangquan / Xing, Zhizhong / Xu, Benda / Xu, Donglian / Xu, Fanrong / Xu, Jilei / Xu, Jing / Xu, Meihang / Xu, Yin / Xu, Yu / Yan, Baojun / Yan, Xiongbo / Yan, Yupeng / Yang, Anbo / Yang, Changgen / Yang, Huan / Yang, Jie / Yang, Lei / Yang, Xiaoyu / Yang, Yifan / Yao, Haifeng / Yasin, Zafar / Ye, Jiaxuan / Ye, Mei / Yegin, Ugur / Yermia, Frédéric / Yi, Peihuai / Yin, Xiangwei / You, Zhengyun / Yu, Boxiang / Yu, Chiye / Yu, Chunxu / Yu, Hongzhao / Yu, Miao / Yu, Xianghui / Yu, Zeyuan / Yuan, Chengzhuo / Yuan, Ying / Yuan, Zhenxiong / Yuan, Ziyi / Yue, Baobiao / Zafar, Noman / Zambanini, Andre / Zeng, Pan / Zeng, Shan / Zeng, Tingxuan / Zeng, Yuda / Zhan, Liang / Zhang, Feiyang / Zhang, Guoqing / Zhang, Haiqiong / Zhang, Honghao / Zhang, Jiawen / Zhang, Jie / Zhang, Jingbo / Zhang, Peng / Zhang, Qingmin / Zhang, Shiqi / Zhang, Tao / Zhang, Xiaomei / Zhang, Xuantong / Zhang, Yan / Zhang, Yinhong / Zhang, Yiyu / Zhang, Yongpeng / Zhang, Yuanyuan / Zhang, Yumei / Zhang, Zhenyu / Zhang, Zhijian / Zhao, Fengyi / Zhao, Jie / Zhao, Rong / Zhao, Shujun / Zhao, Tianchi / Zheng, Dongqin / Zheng, Hua / Zheng, Minshan / Zheng, Yangheng / Zhong, Weirong / Zhou, Jing / Zhou, Li / Zhou, Nan / Zhou, Shun / Zhou, Xiang / Zhu, Jiang / Zhu, Kejun / Zhuang, Honglin / Zong, Liang / Zou, Jiaheng

    A Precision Measurement of the Reactor Antineutrino Spectrum with Sub-percent Energy Resolution

    2020  

    Abstract: The Taishan Antineutrino Observatory (TAO, also known as JUNO-TAO) is a satellite experiment of the Jiangmen Underground Neutrino Observatory (JUNO). A ton-level liquid scintillator detector will be placed at about 30 m from a core of the Taishan Nuclear ...

    Abstract The Taishan Antineutrino Observatory (TAO, also known as JUNO-TAO) is a satellite experiment of the Jiangmen Underground Neutrino Observatory (JUNO). A ton-level liquid scintillator detector will be placed at about 30 m from a core of the Taishan Nuclear Power Plant. The reactor antineutrino spectrum will be measured with sub-percent energy resolution, to provide a reference spectrum for future reactor neutrino experiments, and to provide a benchmark measurement to test nuclear databases. A spherical acrylic vessel containing 2.8 ton gadolinium-doped liquid scintillator will be viewed by 10 m^2 Silicon Photomultipliers (SiPMs) of >50% photon detection efficiency with almost full coverage. The photoelectron yield is about 4500 per MeV, an order higher than any existing large-scale liquid scintillator detectors. The detector operates at -50 degree C to lower the dark noise of SiPMs to an acceptable level. The detector will measure about 2000 reactor antineutrinos per day, and is designed to be well shielded from cosmogenic backgrounds and ambient radioactivities to have about 10% background-to-signal ratio. The experiment is expected to start operation in 2022.

    Comment: 134 pages, 114 figures
    Keywords Physics - Instrumentation and Detectors ; High Energy Physics - Experiment ; Nuclear Experiment
    Subject code 660
    Publishing date 2020-05-18
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top